RYTM (Rhythm Pharmaceuticals) Cyclically Adjusted Book per Share: $4.48 (As of Mar. 2026)


RYTM Rhythm Pharmaceuticals Inc RYTM
56 GF Score
Price $110.42
GF Value $110.90
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Cyclically Adjusted Book per Share?

Rhythm Pharmaceuticals RYTM -0.49% 56 Cyclically Adjusted Book per Share is $4.48 as of Mar. 2026. GuruFocus rates RYTM with a GF Score™ of 56/100 and a GF Value™ of $110.90 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rhythm Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $1.796. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.48 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-02), Rhythm Pharmaceuticals's current stock price is $110.42. Rhythm Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $4.48. Rhythm Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 24.65.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Rhythm Pharmaceuticals was 24.65. The lowest was 18.26. And the median was 19.73.


Rhythm Pharmaceuticals  (NAS:RYTM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rhythm Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=110.42/4.48
=24.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Rhythm Pharmaceuticals was 24.65. The lowest was 18.26. And the median was 19.73.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rhythm Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Rhythm Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.48

RYTM vs MIRM, SYRE, PTGX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


RYTM
56GF Score
Rhythm Pharmaceuticals Inc RYTM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rhythm Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.796/330.2130*330.2130
=1.796

Current CPI (Mar. 2026) = 330.2130.

Rhythm Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201512 -0.307 236.525 -0.429
201609 0.000 241.428 0.000
201612 -1.254 241.432 -1.715
201703 0.000 243.801 0.000
201706 1.372 244.955 1.850
201709 -1.992 246.819 -2.665
201712 5.307 246.524 7.109
201803 4.899 249.554 6.482
201806 8.320 251.989 10.903
201809 7.842 252.439 10.258
201812 7.156 251.233 9.406
201903 6.404 254.202 8.319
201906 5.260 256.143 6.781
201909 4.312 256.759 5.546
201912 6.387 256.974 8.207
202003 5.741 258.115 7.345
202006 5.117 257.797 6.554
202009 4.455 260.280 5.652
202012 3.765 260.474 4.773
202103 7.588 264.877 9.460
202106 7.002 271.696 8.510
202109 6.411 274.310 7.718
202112 5.651 278.802 6.693
202203 4.679 287.504 5.374
202206 3.877 296.311 4.321
202209 5.043 296.808 5.611
202212 4.668 296.797 5.194
202303 3.866 301.836 4.229
202306 3.204 305.109 3.468
202309 3.342 307.789 3.585
202312 2.857 306.746 3.076
202403 1.010 312.332 1.068
202406 0.644 314.175 0.677
202409 0.183 315.301 0.192
202412 0.348 315.605 0.364
202503 0.298 319.799 0.308
202506 -0.186 322.561 -0.190
202509 2.232 324.800 2.269
202512 2.069 324.054 2.108
202603 1.796 330.213 1.796

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $4.48 mean?
Rhythm Pharmaceuticals (RYTM) has a Cyclically Adjusted Book per Share of $4.48 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Rhythm Pharmaceuticals' current Cyclically Adjusted Book per Share is $4.48. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Cyclically Adjusted Book per Share compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Cyclically Adjusted Book per Share of $4.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Cyclically Adjusted Book per Share is $4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $110.90, compared to a current price of $110.42 — trading 0.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is $4.48. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Cyclically Adjusted Book per Share is $4.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of $110.42 is trading 0.4% below its estimated GF Value™ of $110.90. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for RYTM:

  • Cyclically Adjusted Book per Share: $4.48
  • GF Value™: $110.90 vs. price of $110.42 (0.4% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rhythm Pharmaceuticals Business Description

Other Exchanges 1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for RYTM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$110.42
Price
$110.90
GF Value